Abstract 18
Inspired by bioactive biaryl-containing natural products found in plants and the marine 19 environment, a series of synthetic compounds belonging to the azaBINOL chiral ligand family 20 was evaluated for antiviral activity against HIV-1. Testing of 39 unique azaBINOLs in a single-21 round infectivity assay resulted in the identification of three promising antiviral compounds, 22
including 7-isopropoxy-8-(naphth-1-yl)quinoline (azaBINOL B#24), which exhibited low-23 micromolar activity. The active compounds and several close structural analogues were further 24 tested against three different HIV-1 envelope pseudotyped viruses as well as in a full-virus 25 replication system (EASY-HIT). Mode-of-action studies using a time-of-addition assay indicated 26 that azaBINOL B#24 acts after viral entry but before viral assembly and budding. HIV-1 reverse 27 transcriptase (RT) assays that individually test for polymerase and RNase H activity were used to 28 demonstrate that B#24 inhibits RNase H activity, most likely allosterically. Further binding 29 analysis using bio-layer interferometry (BLI) showed that B#24 interacts with HIV-1 RT in a 30 highly specific manner. These results indicate that azaBINOL B#24 is a potentially viable, novel HIV/AIDS continues to be a major global health epidemic. In 2017, there were 36.9 million 39 people living with HIV worldwide and an additional 1.8 million people became newly infected. 1 
40
Despite substantial efforts towards vaccine development, there are currently no FDA-approved 41 vaccines and management of HIV infection requires long-term treatment with potent anti-HIV 42 drugs. 2 Although drug regimens such as antiretroviral therapy (ART) are able to keep HIV viral 43 load low in infected patients, these treatments are typically limited by adverse side effects, 44 increasing drug resistance, high costs, and global availability shortages. 3 Currently, therapeutic 45 antiviral drugs target different phases of the HIV lifecycle including viral attachment, fusion, 46 reverse transcription, integration, and protease activity. Treatments often utilize multiple drugs in 47 combination to combat the rapid emergence of chemoresistant viruses. 3 Therefore, novel 48 therapeutics that act on previously untargeted steps of the viral life cycle are urgently needed to 49 circumvent the onset of drug resistance and to improve treatments. 4 50 HIV reverse transcriptase (RT) has been successfully targeted with first and second-51 generation non-nucleosides reverse transcriptase inhibitors (NNRTIs) as exemplified by 52 nevirapine, first introduced in 1996, and more recently rilpivirine, in 2011. 5, 6 Out of the 27 53 currently FDA approved HIV drugs on the market, 13 of them target RT polymerase activity, 54
including the NNRTIs. 7 However, the reverse transcriptase enzyme is a multifunctional protein 55 and no drugs have been developed yet that target the RT ribonuclease H (RNase H) activity, 56 which has recently been validated as a target for small molecule drug intervention. 8, 9 HIV RT is 57 responsible for converting the single-stranded viral RNA genome to a double-stranded DNA for 58 subsequent integration into the genome of the host cell. The heterodimeric RT protein (p66/p51) 59 has separate active sites for polymerase and RNase H activity. The polymerase starts the 60 synthesis of DNA by first copying the viral RNA genome and forming RNA:DNA hybrids while 61
RNase H catalyzes the degradation of RNA in DNA:RNA hybrids to finally form duplex DNA. 10 62
The RNase H active site contains two bivalent Mg 2+ ions that chelate and cleave the RNA 63 phosphate backbone by directing a nucleophilic water molecule towards the phosphate linkage. 11 64
It has been shown that RNase H activity can be abolished through Mg 2+ chelation in the active 65 site or through allosteric binding near the NNRTI site causing conformational changes. 9 The 66 addition of novel antiviral drugs that target RNase H activity to current combinatorial regimens 67 would introduce a new synergistic method of HIV-1 inhibition greatly improving efficacy of 68 treatment options. 69
To identify novel leads for drug discovery efforts one may look to sources of compounds that 70 have been either infrequent explored or else untapped in prior studies. Notable in this regard are 71 the numerous ostensibly artificial organic molecules that have been introduced as chiral metal 72 ligands and/or organocatalysts for the purpose of facilitating catalytic enantioselective syntheses. 73
The structural features present in such molecules that are necessary for their intended function 74 (e.g., chiral scaffolds with few rotatable bonds, donor sites from atoms with lone pairs, hydrogen-75 bond acceptors and donors, sites of localized charge density, zones of steric encumbrance, etc.) 76 could also lead to meaningful and potentially specific interactions with proteins and other classes 77 of biomolecules involved in various diseases. Axially chiral biaryl compounds based on 1,1´-78 binaphthyl scaffolds are considered a 'privileged' class of reagents for enantioselective synthesis 79 and the principal member of this group, 1,1´-bi-2-naphthol (BINOL, 1), has become one of the 80 most widely used ligands for stoichiometric and catalytic asymmetric reactions. 12 While BINOL 81 itself has previously been found to be cytotoxic, many other biaryl compounds, either found in 82 nature or of artificial origin, have shown potent and selective bioactivities. 13, 14 For example, the 83 axially chiral dimeric naphthylisoquinolone alkaloids first isolated from Anicistrocladus 84 korupensis in 1991 and later named the michellamines, exhibit selective anti-HIV activity. 15-19 85 Given these facts taken together with the existence of other antiviral biaryl natural products (e.g., 86 dioncophylline 20 ) and recently identified synthetic antiviral drug leads with multiple aromatic 87 ring systems (e.g., arbidol, 21 peptide triazoles, 22 rhodanine derivatives, 23 naphthylhydrazones, 24 88 and hydroxypyridones 25 ), we elected to test a library of heterocyclic biaryl compounds available 89 to us and belonging to the so-called 'azaBINOL' chiral ligand family for inhibition of HIV-1 90
infection. 91
The azaBINOLs are nitrogenous analogs of BINOL based on isostructural 8-(naphth-1-92 yl)quinoline (2, 8-azaBINOL) 26 These molecules have been a focus of interest both from a fundamental standpoint 26, 30, 31 and for 94 their potential utility in enantioselective synthesis, 32, 33 but prior to this work, studies of any 95 aspect of the biological activity of azaBINOLs had yet to be reported. Herein, we show that 96 deoxy-8-azaBINOL derivatives provide a novel scaffold for the inhibition of HIV-1 RT RNase H 97 activity. Our lead compound, the isopropyl ether derivative of 2'-deoxy-8-azaBINOL (B#24), 98
shows unoptimized low micromolar activity (4-9 µM range) in an HIV single round infectivity 99 assay as well as in fully infectious viral assays with low cytotoxicity and a selectivity index 100 of 14. 101 A library of 39 unique azaBINOLs and two BINOLs was screened for antiviral HIV-1 125 activity using a pseudo-typed viral particle, single round infectivity assay (HIVpp) (see 126
Supporting Information for full screening data and structures of all library members; all 127 compounds were screened in racemic form and four were additionally evaluated as their 128 enantiopure (aS)-and (aR)-atropisomers). Antiviral activity was compared directly to compound 129 cytotoxicity using a standard MTT-based cell viability assay to assess selectivity indices of 130 compounds. Initial screening efforts at single-dose concentrations (10 µg/mL) of the full 131 compound library revealed three compounds with low micromolar anti-HIV activity: B#24, 132 B#43, and B#60 ( Figure 2 ). These compounds, an isopropyl ether (B#24) and two carbamate 133 derivatives (B#43 and B#60) of deoxy-8-azaBINOL molecules, showed high viral inhibitory 134 activity with only minor cytotoxicity and warranted further investigation. Closer analysis of the 135 compound library revealed three additional azaBINOLs sharing similar structural features to the 136 aforementioned active compounds: a naphthol-type regioisomer of quinol-type ether B#24 137 (B#59), as well as 2-deoxy-8,8´-diazaBINOL congeners of the isopropyl ethers and carbamates 138 (B#57 and B#58). Despite the close structural similarities of these compounds, they showed little 139 antiviral activity as compared to B#24, B#43, and B#60 ( Figure 2 ). HIV antiviral activity was 140 evident for the isopropyl ether and carbamate derivatives of 2-and 2´-deoxy-8-azaBINOL but it 141 was notably completely absent for the corresponding 2-deoxy-8,8´-diazaBINOL series of 142 compounds. Due to the close structural similarities between the active isopropyl ether and 143 carbamate compounds to their non-active counterparts in the HIVpp assay, we decided to move 144 all six compounds forward for further activity explorations. 145 Antiviral activity of the isopropyl ether compounds B#24, B#59, B#57 and the carbamate 146 derivatives B#43, B#60, and B#58 was assessed against three different HIV-1 enveloped pseudo-147 typed particles with differing tropism including HXB2, YU2, and 89.6 ( Table 1 ). All six of the 148 azaBINOL compounds showed similar activities across all viral variants. Quinol-type 2´-deoxy-149 8-azaBINOL ether B#24 in particular showed low micromolar HIV-1 neutralization against each 150 of the strains tested with activity similar to other antiviral drugs such as abacavir. 34 Although the 151 naphthol-type 2-deoxy-8-azaBINOL ether B#59 did show minor antiviral activity at high 152 concentrations, its IC50 was greater than the concentrations tested and significantly larger in 153 comparison to the closely related quinol-type ether B#24, which has an IC50 value of 4 -8 µM. 154
The significant difference in antiviral activity of these two regioisomers (B#24 and B#59) hints 155 towards a highly specific and selective mode of inhibition. The corresponding carbamate 156 derivatives of deoxy-8-azaBINOLs, B#43 and B#60, both showed moderate antiviral activity 157 against all three viral strains but with smaller selectivity indices. Again, neither of the 2-deoxy- Out of the 41 unique compounds originally screened for anti-HIV-1 activity, one compound, 170 quinol-type 2´-deoxy-8-azaBINOL ether B#24, stands out with selective antiviral activity and a 171 favorable selectivity index. Small changes to its structure, including moving the isopropyl ether 172 substituent to the naphthyl ring system (B#59), or the introduction of an additional aromatic ring-173 bound nitrogen atom (B#57), results in drastically reduced antiviral activity. While the deoxy-8-174 azaBINOL carbamate derivatives B#43 and B#60 do exhibit antiviral activity in the phenotypic 175 assays, they also show significant cytotoxicity and therefore their apparent antiviral activity is 176 likely due to interference with the cell-based assay. The low micromolar antiviral activity of lead 177 compound B#24 encouraged us to explore its mode-of-action. 178
AzaBINOLS are not pan-assay interference compounds (PAINS) 179
Promiscuous inhibitors in high-throughput screening endeavors often lead to unproductive 180 identification and development of compounds with non-specific activity. 36 For example, cell-181 based assays requiring a colorimetric out-read can be inhibited through non-specific mechanisms 182 giving false-positive results. 37 The cell-based HIVpp used in this study contains a luciferase 183 reporter out read, so we looked to test the capacity of B#24 to directly inhibit luciferase 184 luminescence in a recombinant luciferase enzyme test (SI Figure 6 ). 38 B#24 showed no inhibition 185 of luciferase activity nor quenching at any concentrations tested verifying that it was not acting 186 on luminescence. Additionally, based on the low solubility and largely hydrophobic surface area 187 of B#24, we sought to probe its ability to inhibit HIV-1 through unspecific aggregation effects. 188
We tested the ability for B#24 to aggregate at higher concentrations in aqueous conditions via an 189 1 H-NMR dilution study (SI Figure 7) . 39 Five concentrations of B#24 were tested from 200 µM to 190 12 µM in 50 mM phosphate buffer made with D2O and 1% DMSO-d6. No changes were seen in 191 the number of resonances, peak shape, or chemical shift values indicating that B#24 does not 192 aggregate under the test conditions. 193
Time-of-addition assay 194
The single round infectivity assay using HIV-1 enveloped pseudotyped viruses is able to 195 report on inhibition of early stages of infection including cell entry, reverse transcription, and Next, we sought to explore viral enzyme interactions directly to verify if B#24 interacts with the 209 HIV RT dual functions (DNA polymerase and/or RNase H activity) or HIV integrase. 210
Activity of B#24 against HIV-1 reverse transcriptase 211
NNRTI binding to the HIV RT enzyme occurs at a distant, allosteric binding site and the 212 long-distance effects on the RT polymerase activity are well documented. 10 In contrast, inhibitors 213 of the HIV RT enzyme that target its RNase H function directly affect the catalytic side with its 214 Mg 2+ ions, and therefore are often dual inhibitors, with effects on reverse transcriptase and 215 integrase as both require bivalent metals in their active site. We screened B#24 for inhibitory 216 activity in recombinant protein-based assays to test for HIV-1 RT and/or integrase antiviral 217 inhibition (Table 3) . AzaBINOL B#24 showed no effect against HIV-1 integrase activity in a 218 commercially available kit (ExpressBio, Frederick, MD) at any concentration tested up to 200 219 µM. When tested against an HIV-1 RT polymerase assay we observed only weak inhibitory 220 effects for B#24 at concentrations higher than 100 µM, several orders of magnitude weaker than 221 seen in our cell-based assays. 222
However, since RNase H activity, the second catalytic activity of the HIV-1 reverse 223 transcriptase, is not detected in the above RT-polymerase assay, we investigated the effect of 224 B#24 on RNase H activity using a previously reported FRET based approach. 40, 41 Here, we used 225 a pair of oligonucleosides including an 18-mer strand of RNA containing a 3'-fluorescein 226 modification and an 18-mer strand of DNA with a 5'-dabcyl quencher modification. When RNA 227 is cleaved from the RNA/DNA hybrid by RNase H activity, the fluorescent probe is removed 228 from its quenching partner (dabcyl) resulting in fluorescence. We found that B#24 inhibited 229
RNase H activity of HIV RT with an IC50 of 14.2 µM, within the same range as the low 230 micromolar cell-based assay results (Table 3) . 231
Several classes of compounds have shown promising antiviral activity by acting on RNase H 232
activity including N-hydroxyimides, 42 properties. 8, 9 Compound B#24 was tested for Mg 2+ binding by assessment of its UV absorption 239 under an increasing concentration of Mg 2+ following existing procedures. 50 No UV absorbance 240 changes were observed with the addition of Mg 2+ up to 120 mM with B#24 (100 µM) ( Figure 4) . 241
Therefore, we conclude that B#24 is not interacting with Mg 2+ ions and subsequently is not 242 inhibitors and therefore allow for a more favorable therapeutic window. 8, 9 249
HIV-1 reverse transcriptase binding 250
To show that B#24 inhibits RNase H activity by binding the HIV-1 reverse transcriptase 251 enzyme, we explored direct binding to immobilized HIV-1 RT using bio-layer interferometry 252 (BLI). BLI allows for the real time measurement of binding affinities between ligands and 253 analytes of varying size using single-use, fiber optical sensors. BLI measures association (kon) 254 and dissociation (koff) rates directly from full spectrum wavelength shifts associated with 255 interference pattern changes derived from binding events at a sensors tip to determine binding 256 affinities (KD). 54 Recombinant-wild type HIV-1 p66/p51 RT (NIH Aids Reagents) was 257 immobilized via amine coupling onto BLI biosensors. B#24, selected other azaBINOLs, and 258 control compounds (rilpivirine positive control, raltegravir negative control) were prepared in 1x 259 kinetics buffer at multiple concentrations. Each compound was tested at multiple concentrations, 260 responses were globally fit using a 1:1 binding model, and these fits were used to calculate KD 261 values. The binding curves obtained for B#24 are shown in Figure 5 . In good agreement with 262 cell-based antiviral assays, B#24 shows a concentration-dependent binding to HIV-1 RT. Control 263 compound rilpivirine also showed concentration dependent binding curves while raltegravir, an 264
HIV-1 integrase inhibitor showed no binding at any concentration tested as expected (SI Figure  265   4 ). Although the acquired KD of 38 µM associated with B#24 is higher than the IC50 in cell-based 266 assays, it should be noted that the affinity value cannot be directly related to neutralization 267 efficacy, as seen in many high-affinity, non-neutralizing HIV antibodies. [55] [56] [57] No binding was 268 observed for the related azaBINOLs of interest from the compound library (SI Figure 7) . In 269 summary, the BLI binding data obtained reveals a striking correlation between the binding 270 affinity of B#24 towards its target HIV RT and its antiviral activity. 271
Discussion and conclusion 272
RNase H inhibition of HIV-1 RT is an under explored and under-utilized mechanism of 273 inhibition. The azaBINOL compounds reported here represent novel scaffolds that inhibit HIV 274 via an underexplored allosteric mechanism with low toxicity and high specificity. In particular, 275 the isopropyl ether derivative of 2´-deoxy-8-azaBINOL (B#24) exhibits with potent and specific 276 antiviral activity against HIV RNase H. We utilized time-of-addition experiments and 277 recombinant enzyme assays to show that B#24 specifically inhibits RNase H. In addition, we 278 used BLI to show that B#24 binds to HIV RT via a 1:1 binding mechanism with a binding 279 affinity (KD) of 38 µM. Although a number of azaBINOL compounds within the screened library 280 were found to have limited solubility in the cell-based assays as expected, aggregation and non-281 specific inhibition was tested thoroughly and can be dismissed for lead compound B#24 (SI Fig  282   6,7) . Future studies are planned to optimize the azaBINOL core structure to increase HIV-1 299 activity by improving HIV-1 binding, solubility, and to reduce cytotoxicity. It is anticipated that 300 the absolute configuration of the biaryl system will influence biological activity but to what 301
extent remains an open question since a majority of the compounds evaluated herein were tested 302 in racemic form only. Work is in progress to determine the configurational stability of 303 compounds such as B#24 and bioassays of these materials in enantioenriched form will be 304 conducted should their racemization half-lives prove to be high enough for such an effort to be 305
meaningful. 306
In summary, we discovered that an isopropyl ether derivative of an aza-analog of the 307 archetypal axially chiral biaryl ligand BINOL, inhibits HIV-1 infection in vitro. Based on the 308 identified RNase H inhibition, direct HIV-1 RT binding, and the known hydrophobic binding 309 surfaces associated with allosteric inhibiton, 58 we believe that B#24 is a novel allosteric inhibitor 310 of HIV-1 RT-RNase H activity. While biaryl compounds of natural origin have long been known 311 to exhibit significant biological activity, 14, 61 this study suggests that further investigations of the 312 bioactivity of artificial biaryls, designed purely with synthetic utility in mind, are warranted. (Brentford, UK). All compounds received were tested for purity and identity via LCMS analysis 347 before use. 348
Synthesis of new compounds and characterization data. 349
Representative procedure for preparation of isopropyl ethers. 7-(Isopropyloxy)-8-(naphth- (0.080 mL, d = 1.07, 86 mg, 0.632 mmol). The resulting solution was heated to 100 °C and 397 stirred for 24 h. After this time, the mixture was allowed to cool to rt and partitioned between 398 EtOAc (10 mL), H2O (15 mL) and sat. aq. NaHCO3 (5 mL). The aqueous phase was extracted 399 with EtOAc (10 mL) and the combined organic phases washed with H2O (5 mL) and brine (5 400 mL), then dried (Na2SO4) and concentrated in vacuo. 
Pseudovirus production. 432
HIV-1 pseudotyped viruses were prepared as previously described. 68 Briefly, HEK 293T 433 cells were transfected with an envelope expression plasmid (pHxB2, pYU2, or p89.6) and an 434 envelope deficient HIV-1 backbone vector (pSG3Δenv) using XtremeGENE HP DNA 435
Transfection Reagent (Roche). After 24 hours of incubation at 37°C and 5% CO2, the growth 436 media was replaced with fresh media followed by an additional 24 hours of incubation. Cellular 437 supernatant was collected and passed through a 0.45 µm filter to give pseudoviral stock. 1 mL 438 pseudoviral aliquots were stored at -80°C until further use in neutralization assays. Viral strength 439 was determined through TCID50 calculations. TZM-bl cells were plated at 9000 cells per well in 440 white 96 well plates (Greiner Bio-One) and incubated at 37 C, 5% CO2 for 24 hours. HIV-1 441 pseudoviruses were added over a two-fold dilution series to wells. At 48 hours-post infection, 442 cells were lysed and BrighGlo luciferase substrate (Promega) added. Luminescence reading were 443 immediately recorded and the TCID50 value calculated as 50% of the maximum light output 444 based on control wells. 445
HIV-1 pseudovirus single-round infectivity assay. 446
Viral infection rates of HIV-1 pseudoviruses in the presence of inhibitors was measured 447 through HIV-1 pseudoviral tat-induced luciferase production in TZM-bl cells as described 448
previously. 68 TZM-bl cells were plated at 9000 cells/well into 96 well plates (excluding outer 449 wells to avoid edge effects) followed by overnight incubation at 37°C, 5% CO2. Inhibitors and 450 pseudoviral particles at a final concentration of 1x (based on TCID50 measurements) were 451 incubated together for 20 min prior to transfer to adherent TZM-bl cells followed by 48 hours 452 incubation at 37°C, 5% CO2. Viral infection was quantified based on luminescent readings taken 453
immediately after the addition of BrighGlo luciferin substrate to infected cells in lysis buffer and 454 relative infectivity rates calculated based on infectious and noninfectious vehicle control wells 455 (1% DMSO). Antiviral IC50 values were calculated from compound dilution series ran in 456 triplicate. 457
HIV Full virus Screening (EASY-HIT). 458
The EASY-HIT assay 35 is based on HIV-1 susceptible reporter cells (LC5-RIC) that contain 459 a stably integrated fluorescent reporter gene that is activated upon successful HIV-1 infection 460 and expression of the early viral protein Rev and Tat. Briefly, LC5-RIC cells were seeded into 461 black 96-well plates at a density of 10,000 cells per well 24 hours prior to infection. Compounds 462 stocks dissolved at 20 mM in DMSO were screened at multiple concentrations from 0.1 to 200 463 µM at a final DMSO concentration of 1% to establish IC50 curves. After compound addition, 464 LC5-RIC cells were infected by adding HIV-1 inoculum at an MOI of 0.5 to each well of the 465 plate. Cells were incubated at 37°C, 5% CO2 for 48 hours after infection and then measured for 466 reporter expression. Reporter expression was determined by measuring the total fluorescent 467 signal intensity of each well using a fluorescence microplate reader at an excitation filter 468 wavelength of 552 nm and an emission filter wavelength of 596 nm. 469
Cell viability assays. 470
Cell viability of TZM-bl cells was determined by monitoring mitochondrial reductase 471 activity from the reduction of the tetrazolium salt MTT by metabolically active cells. 69 TZM-bl 472 cells were plated into 96 well plates (Greiner Bio-One) followed by overnight incubation at 473 37°C, 5% CO2. Compounds were added to wells with a final DMSO concentration of 1% 474 followed by an additional 48 hours incubation. After the designated incubation time, MTT 475 reagent (5mg/mL in 1x PBS) was added to each well to a final concentration of 0.5 mg/mL. 476
MTT containing plates were incubated for an additional 3 hours after which the media was 477 removed, and the reduced purple formazan product dissolved in 50 µL DMSO. Absorbance was 478 measured at 550 nm. Metabolic activity of vehicle-treated cells (1% DMSO) was defined as 479 100% cell growth. Cell viability of LC5-RIC cultures exposed to HIV inoculum and test 480 compounds was determined by performing a CellTiter-Blue® cell viability assay (Promega) and 481 monitoring the ability of metabolically active cells to convert the redox dye resazurin into the 482 fluorescent product resorufin. LC5-RIC cells were plated into black 96 well plates (Greiner Bio- and 0.05% sodium azide, FortéBio). Binding affinity (KD) was characterized through the analysis 533 of association and dissociation curves at multiple concentrations. All samples were tested in 534 duplicate. Rilpivirine was used as a positive binding control, raltegravir as a negative control. 535
Effects from non-specific binding were removed using double referencing. Residual baseline 536 drift was calculated by fitting the response during baseline periods to an exponential decay and 537 then subtracting this drift. The resulting response curves were globally fit to a 1:1 Langmuir 538 model. 72 All fits were performed using a constrained, non-linear least squares minimization 539 (MATLAB R2018a, lsqnonlin function implementing the trust region reflective algorithm). 540
Constraints on parameters were used to guide convergence away from non-physical parameter 541 values, but all constraints were inactive at the converged optimum. A parametric bootstrap 542 analysis was used to compute a 95% confidence interval for the computed KD values, using a 543 normally-distributed error with variance estimated from the sum of squared residuals of the 544 model fit (MATLAB R2018a, 100 iterations). Random noise in response curves was filtered 545 prior to plotting using a smoothing spline (MATLAB R2018a, spaps function). 546
Bivalent metal binding assay. 547
Testing for complexation of B#24 with Mg 2+ ions was carried out following previous 548 protocols with adjustments. 50 In brief, a 1 M stock solution of MgCl2 and a 1 M solution of B#24 549 were prepared in 1:1 ethanol/acetonitrile mixtures. B#24 was diluted to 100 µM and UV 550 absorbance readings recorded using a BioTek synergy plate reader from 200 -400 nm. 10 µL 551 additions of a 500 mM Mg 2+ solution containing 100 µM B#24 (to keep compound concentration 552 consistent) was added stepwise followed by absorbance readings between each addition. The 553 concentration of Mg 2+ was raised with each addition from 0.5 mM to 120 mM. Alignment, 554 reference subtraction of blanks, and plotting were done on raw data using Microsoft Excel. 555
Luminescence inhibition assays. 556
To determine if B#24 was capable of non-specifically inhibiting luciferase activity in the 557 HIV-1 pseudotyped assay, we implemented a cell-free assay with purified recombinant luciferase 558 (Promega) and luciferin (BrightGlo Luciferase Assay System; Promega) following a previous 559 protocol. 38 Protein and reagents were prepared and stored according to manufacturer's 560 instructions. Preliminary experiments established the concentration of luciferin to be used in the 561 assay in order to closely mimic the protein signal in single-round infectivity assay and give 562 maximal sensitivity in luminescence readings. Reactions were carried out in white 96 well-plates 563 (Gibco; ThermoFisher Scientific) by combining compounds with 0.5 µg/mL recombinant 564 luciferase in 1x PBS buffer and 1 mg/mL BSA (VWR). Reactions were initiated by the addition 565 of 30 µL luciferin substrate to wells. Luminescence readings were immediately recorded and 566 normalized using appropriate controls with vehicle solvent (1% DMSO). The compounds 567
Luciferase Inhibitor I (VWR) and raltegravir (NIH Aids Reagent Program) were used as positive 568 and negative controls respectively. 569
Compound aggregation assessment. 570
We observed precipitation of some azaBINOL compounds at concentrations higher than 200 571 µM in cell media with 1% DMSO. To assess if the antiviral activity from the active azaBINOL 572 compound B#24 could be due to non-specific aggregation effects, an 1 H-NMR assay was 573 implemented to characterize compound behavior in aqueous conditions as described 574 previously. 39 Briefly, B#24 was solubilized in DMSO-D6 (MilliporeSigma; Burlington, MA) to a 575 concentration of 20 mM. Serial dilution in 50 mM sodium phosphate at pH 6.8 in 100% D2O 576 
